Glenmark Pharmaceuticals Inc., USA has recalled 15,456 cartons of Rizatriptan Benzoate Tablets USP (rizatriptan benzoate), a medication used to treat migraine headaches. The recall includes both 5 mg and 10 mg strengths in unit-dose packages of 18 tablets. Testing discovered that the medication contains an impurity called N-Nitroso Desmethyl Rizatriptan at levels that are higher than the safety limits established by the FDA.
The tablets contain a nitrosamine impurity at levels exceeding the FDA's acceptable limit. While no immediate health issues have been reported, long-term exposure to certain nitrosamines above safety thresholds may increase the risk of developing cancer.
You have 2 options:
Recall #: D-0532-2024
Recall #: D-0533-2024
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.